Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05067556 | Decreasing Long-term Opioid Use in Cancer Survivors | N/A | suspended | Oct 5, 2021 | Virginia Commonwealth University | Insufficient staffing | Other (stated, no rule matched) |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Jun 28, 2022 | T-ACE Medical Co., Ltd | T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug… | Other (stated, no rule matched) |
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM…(HU-F-AIM) | Phase 4 | terminated | May 10, 2023 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT06477003 | Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer(OUSCCMOTORX) | N/A | suspended | Jun 27, 2024 | University of Oklahoma | Administrative reasons. | Other (stated, no rule matched) |
| NCT07629921 | Multimodal Al for Precision Diagnosis of Esophageal Cancer | — | terminated | Jun 5, 2026 | Shanghai Zhongshan Hospital | local ethics review | Other (stated, no rule matched) |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid… | Phase 1 | suspended | Apr 12, 2021 | National Cancer Institute (NCI) | Other - Pending amendment. | Other (stated, no rule matched) |
| NCT05130866 | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2…(POPLAR-NF2) | Phase 2 / Phase 3 | terminated | Nov 23, 2021 | Recursion Pharmaceuticals Inc. | Study was terminated due to sponsor decision. This decision was not related to safety concerns with… | Safety / toxicity |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | Phase 2 | withdrawn | Jun 21, 2022 | Andrei Iagaru | logistical issues | Other (stated, no rule matched) |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | Phase 2 | suspended | Nov 7, 2022 | Case Comprehensive Cancer Center | On hold per study team | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT07173101 | Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on…(HEADBAND) | Phase 2 | terminated | Sep 15, 2025 | University of Utah | Safety Review | Safety / toxicity |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | withdrawn | Feb 4, 2026 | Thomas Jefferson University | FDA requested significant changes to the study protocol | Other (stated, no rule matched) |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab,… | Phase 1 | terminated | Oct 19, 2021 | Astellas Pharma Global Development, Inc. | Lack of clinical benefit | Efficacy / futility |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT05842031 | Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal… | — | suspended | May 3, 2023 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05904899 | An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New… | — | suspended | Jun 15, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06052345 | Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors,…(CIPN-REBECCA) | — | withdrawn | Sep 25, 2023 | Theodoros Foukakis | No accrual | Enrollment / accrual |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | Phase 1 | withdrawn | Nov 10, 2021 | Guizhou Bailing Group Pharmaceutical Co Ltd | Withdrawn due to duplicate registration | Other (stated, no rule matched) |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT05873699 | Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 1 | suspended | May 24, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to… | — | terminated | Aug 12, 2024 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2024 | Kevin McNerney | The trial has been stopped pending FDA approval of modifications to the trial protocol. | Other (stated, no rule matched) |
| NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Jan 21, 2026 | Merus B.V. | This study-level decision was based on the evolving treatment landscape and strategic portfolio… | Safety / toxicity |
| NCT07655284 | STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy | Phase 3 | withdrawn | Jun 17, 2026 | Brigham and Women's Hospital | Study withdrawn prior to enrollment. Principle Investigator changed institutions prior to obtaining… | Investigator |
| NCT02393833 | IBCSG Trial 22-00 Serum Substudy | N/A | terminated | Mar 19, 2015 | ETOP IBCSG Partners Foundation | Sufficient statistical power cannot be met due to low samples size | Other (stated, no rule matched) |
| NCT04007640 | Early Screening of Pancreatic Lesions : Development of New Imaging Tools(PAIR-PANCREAS) | N/A | terminated | Jul 5, 2019 | Assistance Publique - Hôpitaux de Paris | Population difficult to recruit; number of enrolled patients sufficient for analyses. | Enrollment / accrual |
| NCT04017819 | Biodistribution & Pharmacokinetic of Position Emission Tomography (PET)… | Phase 1 | suspended | Jul 12, 2019 | Stanford University | funding | Funding |
| NCT04605614 | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Phase 1 | withdrawn | Oct 28, 2020 | City of Hope Medical Center | slow accruals | Enrollment / accrual |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… | Phase 2 | terminated | Apr 4, 2022 | Providence Health & Services | PI opted to close study due to poor accrual. | Enrollment / accrual |
| NCT05491317 | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment… | Phase 1 / Phase 2 | terminated | Aug 8, 2022 | Genmab | After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed… | Efficacy / futility |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT06162663 | Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for… | Phase 4 | terminated | Dec 8, 2023 | Medical University of South Carolina | Terminated early due to insufficient accrual to meet prespecified statistical analysis requirements. | Enrollment / accrual |
| NCT06489769 | Opioid Misuse in Patients With Cancer | — | suspended | Jul 8, 2024 | Rigshospitalet, Denmark | Enrollment suspended due to insufficient recruitment resulting from staffing shortages and… | Enrollment / accrual |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | N/A | withdrawn | Sep 24, 2024 | Scripps Health | no patients were able to be enrolled | Enrollment / accrual |
| NCT01437787 | Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis(JAKARTA) | Phase 3 | terminated | Sep 21, 2011 | Bristol-Myers Squibb | not stated | Not stated |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered… | Phase 1 | terminated | Nov 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05591092 | Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular… | — | terminated | Oct 24, 2022 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors… | Phase 1 / Phase 2 | terminated | Apr 30, 2024 | Genmab | Terminated due to strategic decision | Sponsor / business decision |
| NCT03164460 | Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in… | Phase 2 | suspended | May 23, 2017 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04106973 | Mesothelioma Early Detection by VOCs(MED-VOC) | — | terminated | Sep 27, 2019 | Henry Ford Health System | Recruitment suspended secondary to social distancing directive associated with Covid-19 | COVID-19 / pandemic |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid… | Phase 1 / Phase 2 | terminated | Sep 17, 2020 | Tianhong Li | Terminated early by the Sponsor due to business reason. | Sponsor / business decision |
| NCT05201014 | Cancer Survivor Cardiomyopathy Detection(CASCADE) | — | terminated | Jan 21, 2022 | Mayo Clinic | diminished funding | Funding |
| NCT06205888 | To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT(18F-LNC1007) | — | withdrawn | Jan 16, 2024 | Jinling Hospital, China | No participants | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 18, 2026source: clinicaltrials